Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
BMC Cancer|July 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, et al.
BMC Medical Research Methodology|May 3, 2025
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trialCharlotte Gaskell, Kim Linton, Mark Bishton, et al.
BMC Cancer|March 20, 2025
Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trialRobin J Young, Amanda Kirkham, Joshua Savage, et al.
BMC Cancer|January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trialGraham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
BMJ Open|January 29, 2025
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)Ronjon Chakraverty, Emma Kempshall, Fiona Dignan, et al.
BMC Cancer|March 26, 2024
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trialGraham McIlroy, Siân Lax, Charlotte Gaskell, et al.
British Journal of Cancer|September 8, 2023
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strataPenella J Woll, Piers Gaunt, Charlotte Gaskell, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
Pageof 2